Physiologically based pharmacokinetic modeling (PBPK) to predict drug-drug interactions for encorafenib. Part II. Prospective predictions in hepatic and renal impaired populations with clinical inhibitors and inducers

References

• Betrosian AP, Agarwal B, Douzinas EE. 2007. Acute renal dysfunction in liver diseases. World J Gastroenterol. 13(42):5552–5559. doi: 10.3748/wjg.v13.i42.5552.
   PubMed Web of Science ®Google Scholar
• Bhatnagar S, Mukherjee D, Salem AH, Miles D, Menon RM, Gibbs JP. 2021. Dose adjustment of venetoclax when co-administered with posaconazole: clinical drug–drug interaction predictions using a PBPK approach. Cancer Chemother Pharmacol. 87(4):465–474. doi: 10.1007/s00280-020-04179-w.
   PubMed Web of Science ®Google Scholar
• Chen Y, Cabalu TD, Callegari E, Einolf H, Liu L, Parrott N, Peters SA, Schuck E, Sharma P, Tracey H, et al. 2019. Recommendations for the Design of Clinical Drug–Drug Interaction Studies With Itraconazole Using a Mechanistic Physiologically‐Based Pharmacokinetic Model. CPT Pharmacometrics Syst Pharmacol. 8(9):685–695. doi: 10.1002/psp4.12449.
   PubMedGoogle Scholar
• Clinical Trial. 2021. Hepatic impairment study of encorafenib in combination with binimetinib in BRAF melanoma. [accessed 2023 Jun 15]. https://classic.clinicaltrials.gov/ct2/show/NCT04759846.
   Google Scholar
• Cui C, Valerie Sia JE, Tu S, Li X, Dong Z, Yu Z, Yao X, Hatley O, Li H, Liu D, et al. 2021. Development of a physiologically based pharmacokinetic (PBPK) population model for Chinese elderly subjects. Br J Clin Pharmacol. 87(7):2711–2722. doi: 10.1111/bcp.14609.
   PubMed Web of Science ®Google Scholar
• Del Frari L, Lukacova V, Reddy M. 2023. Real world impact + regulatory decision making track poster presentation: building of encorafenib physiologically based pharmacokinetic model and its qualification to predict drug drug interaction with posaconazole. MIDD 2023. Conference, Simulations-Plus. [accessed 2023 Jun 15]. https://www.simulations-plus.com/wp-content/uploads/Laurence_DelFrari-MIDD_16FEB2023.pdf.
   Google Scholar
• Dummer R, Ascierto PA, Gogas HJ, Arance A, Mandala M, Liszkay G, Garbe C, Schadendorf D, Krajsova I, Gutzmer R, et al. 2018. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 19(10):1315–1327. doi: 10.1016/S1470-2045(18)30497-2.
   PubMed Web of Science ®Google Scholar
• El-Khateeb E, Darwich AS, Achour B, Athwal V, Rostami-Hodjegan A. 2021. Review article: time to revisit Child-Pugh score as the basis for predicting drug clearance in hepatic impairment. Aliment Pharmacol Ther. 54(4):388–401. doi: 10.1111/apt.16489.
   PubMed Web of Science ®Google Scholar
• EMA. 2013. Guideline on the investigation of drug interactions. [accessed 2023 Jun 15]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-investigation-drug-interactions-revision-1_en.pdf.
   Google Scholar
• EMA. 2018a. Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation. [accessed 2023 Jun 15]. https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-reporting-physiologically-based-pharmacokinetic-pbpk-modelling-simulation_en.pdf.
   Google Scholar
• EMA. 2018b. Encorafenib summary of product characteristics. [accessed 2023 Jun 15]. https://www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf.
   Google Scholar
• EMA. 2018c. Encorafenib public assessment report. [accessed 2023 Aug 4]. https://www.ema.europa.eu/en/documents/assessment-report/braftovi-epar-public-assessment-report_en.pdf.
   Google Scholar
• Ervine CM, Houston JB. 1994. Disposition of azole antifungal agents. III. Binding of fluconazole and other azoles in rat liver. Pharm Res. 11(7):961–965. doi: 10.1023/a:1018918917046.
   PubMed Web of Science ®Google Scholar
• Franchetti Y, Nolin TD. 2020. Dose optimization in kidney disease: opportunities for PBPK modeling and simulation. J Clin Pharmacol. 60 Suppl 1(S1):S36–S51. doi: 10.1002/jcph.1741.
   PubMed Web of Science ®Google Scholar
• Gerner B, Scherf-Clavel O. 2021. Physiologically based pharmacokinetic modelling of cabozantinib to simulate enterohepatic recirculation, drug–drug interaction with rifampin and liver impairment. Pharmaceutics. 13(6):778. doi: 10.3390/pharmaceutics13060778.
   PubMed Web of Science ®Google Scholar
• Gill J, Moullet M, Martinsson A, Miljković F, Williamson B, Arends RH, Pilla Reddy V. 2022. Comparing the applications of machine learning, PBPK, and population pharmacokinetic models in pharmacokinetic drug–drug interaction prediction. CPT Pharmacometrics Syst Pharmacol. 11(12):1560–1568. doi: 10.1002/psp4.12870.
   PubMedGoogle Scholar
• Guest EJ, Aarons L, Houston JB, Rostami-Hodjegan A, Galetin A. 2011. Critique of the two-fold measure of prediction success for ratios: application for the assessment of drug-drug interactions. Drug Metab Dispos. 39(2):170–173. doi: 10.1124/dmd.110.036103.
   PubMed Web of Science ®Google Scholar
• Heimbach T, Chen Y, Chen J, Dixit V, Parrott N, Peters SA, Poggesi I, Sharma P, Snoeys J, Shebley M, et al. 2021. Physiologically-based pharmacokinetic modeling in renal and hepatic impairment populations: a pharmaceutical industry perspective. Clin Pharmacol Ther. 110(2):297–310. doi: 10.1002/cpt.2125.
   PubMed Web of Science ®Google Scholar
• Hsu CY, Chertow GM, Curhan GC. 2002. Methodological issues in studying the epidemiology of mild to moderate chronic renal insufficiency. Kidney Int. 61(5):1567–1576. doi: 10.1046/j.1523-1755.2002.00299.x.
   PubMed Web of Science ®Google Scholar
• Johnson TN, Boussery K, Rowland-Yeo K, Tucker GT, Rostami-Hodjegan A. 2010. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin Pharmacokinet. 49(3):189–206.
   PubMed Web of Science ®Google Scholar
• Koelblinger P, Thuerigen O, Dummer R. 2018. Development of encorafenib for BRAF-mutated advanced melanoma. Curr Opin Oncol. 30(2):125–133. doi: 10.1097/CCO.0000000000000426.
   PubMed Web of Science ®Google Scholar
• Kollipara S, Ahmed T, Sivadasu P. 2023a. Physiologically based pharmacokinetic modeling to predict drug-drug interactions for encorafenib. Part I. Model Building, Validation and Prospective Predictions with Enzyme Inhibitors, Inducers and Transporter Inhibitors. Xenobiotica. Accepted Manuscript. doi: 10.1080/00498254.2023.2250856
   Google Scholar
• Kollipara S, Bhattiprolu AK, Boddu R, Ahmed T, Chachad S. 2023b. Best practices for integration of dissolution data into physiologically based biopharmaceutics models (PBBM): a biopharmaceutics modeling scientist perspective. AAPS Pharm Sci Tech. 24(2):59. doi: 10.1208/s12249-023-02521-y.
   PubMed Web of Science ®Google Scholar
• Krens SD, Lassche G, Jansman FGA, Desar IME, Lankheet NAG, Burger DM, Van Herpen CML, Van Erp NP. 2019. Dose recommendations for anticancer drugs in patients with renal or hepatic impairment. The Lancet Oncol. 20(4):e200–e207. doi: 10.1016/S1470-2045(19)30145-7.
   PubMed Web of Science ®Google Scholar
• Liu L, Bello A, Dresser MJ, Heald D, Komjathy SF, O'Mara E, Rogge M, Stoch SA, Robertson SM. 2016. Best practices for the use of itraconazole as a replacement for ketoconazole in drug–drug interaction studies. J Clin Pharmacol. 56(2):143–151. doi: 10.1002/jcph.562.
   PubMed Web of Science ®Google Scholar
• Lukacova V, Parrott NJ, Lave T, Franczkiewicz G, Bolger MB, Woltosz WS. 2008. General approach to calculation of tissue: plasma partition coefficients for physiologically based pharmacokinetic (PBPK) modeling. [accessed 2023 Jun 15]. https://www.simulations-plus.com/wp-content/uploads/Lukacova-General_Approach_Calc_Tissue_Plasma_Partition_Coefficients_PBPK_Modeling-AAPS-2008-1.pdf.
   Google Scholar
• Maharaj AR, Barrett JS, Edginton AN. 2013. A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. Aaps J. 15(2):455–464. doi: 10.1208/s12248-013-9451-0.
   PubMed Web of Science ®Google Scholar
• Marques L, Vale N. 2023. Prediction of CYP-mediated drug interaction using physiologically based pharmacokinetic modeling: a case study of salbutamol and fluvoxamine. Pharmaceutics. 15(6):1586. doi: 10.3390/pharmaceutics15061586.
   PubMed Web of Science ®Google Scholar
• Marsousi N, Desmeules JA, Rudaz S, Daali Y. 2017. Usefulness of PBPK modeling in incorporation of clinical conditions in personalized medicine. J Pharm Sci. 106(9):2380–2391. doi: 10.1016/j.xphs.2017.04.035.
   PubMed Web of Science ®Google Scholar
• Naga D, Parrott N, Ecker GF, Olivares-Morales A. 2022. Evaluation of the success of high-throughput physiologically based pharmacokinetic (HT-PBPK) modeling predictions to inform early drug discovery. Mol Pharm. 19(7):2203–2216. doi: 10.1021/acs.molpharmaceut.2c00040.
   PubMed Web of Science ®Google Scholar
• Palatini P, Martin SD. 2016. Pharmacokinetic drug interactions in liver disease: an update. World J Gastroenterol. 22(3):1260–1278. doi: 10.3748/wjg.v22.i3.1260.
   PubMed Web of Science ®Google Scholar
• Parkinson A, Mudra DR, Johnson C, Dwyer A, Carroll K. 2004. The effects of gender, age, ethnicity, and liver cirrhosis on cytochrome P450 enzyme activity in human liver microsomes and inducibility in cultured human hepatocytes. Toxicol Appl Pharmacol. 199(3):193–209. doi: 10.1016/j.taap.2004.01.010.
   PubMed Web of Science ®Google Scholar
• Piscitelli J, Hens B, Tomaszewska I, Wollenberg L, Litwiler K, McAllister M, Reddy M. 2023. Effect of food and a proton-pump inhibitor on the absorption of encorafenib: an in vivo–in vitro–in silico approach. Mol Pharm. 20(5):2589–2599. doi: 10.1021/acs.molpharmaceut.3c00016.
   PubMed Web of Science ®Google Scholar
• Poulin P, Haddad S. 2011. Microsome composition-based model as a mechanistic tool to predict nonspecific binding of drugs in liver microsomes. J Pharm Sci. 100(10):4501–4517. doi: 10.1002/jps.22619.
   PubMed Web of Science ®Google Scholar
• Ren HC, Sai Y, Chen T, Zhang C, Tang L, Yang CG. 2022. Predicting the drug-drug interaction mediated by CYP3A4 inhibition: method development and performance evaluation. Aaps J. 24(1):12. doi: 10.1208/s12248-021-00659-w.
   Web of Science ®Google Scholar
• Rodgers T, Rowland M. 2006. Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 95(6):1238–1257. doi: 10.1002/jps.20502.
   PubMed Web of Science ®Google Scholar
• USFDA. 2003. Pharmacokinetics in patients with impaired hepatic function: study design, data analysis, and impact on dosing and labeling. [accessed 2023 Jun 15]. https://www.fda.gov/media/71311/download.
   Google Scholar
• USFDA. 2018a. Encorafenib multi-disciplinary review. [accessed 2023 Jun 15]. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2018/210496Orig1s000MultidisciplineR.pdf.
   Google Scholar
• USFDA. 2018b. Encorafenib label. [accessed 2023 Jun 15]. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210496s006lbl.pdf.
   Google Scholar
• USFDA. 2020a. The use of physiologically based pharmacokinetic analyses-biopharmaceutics applications for oral drug product development, manufacturing changes, and controls guidance for industry. [accessed 2023 Jun 15]. https://www.fda.gov/media/142500/download.
   Google Scholar
• USFDA. 2020b. Clinical drug interaction studies-cytochrome P450 enzyme- and transporter-mediated drug interactions. [accessed 2023 Jun 15]. https://www.fda.gov/media/134581/download.
   Google Scholar
• USFDA. 2020c. Guidance for industry pharmacokinetics in patients with impaired renal function-study design, data analysis, and impact on dosing. [accessed 2023 Jun 15]. https://www.fda.gov/media/78573/download.
   Google Scholar
• USFDA. 2023. Drug development and drug interactions | table of substrates, inhibitors and inducers. [accessed 2023 Jun 15]. https://www.fda.gov/drugs/drug-interactions-labeling/drug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers.
   Google Scholar
• Watanabe A, Ishizuka T, Yamada M, Igawa Y, Shimizu T, Ishizuka H. 2022. Physiologically based pharmacokinetic modelling to predict the clinical effect of CYP3A inhibitors/inducers on esaxerenone pharmacokinetics in healthy subjects and subjects with hepatic impairment. Eur J Clin Pharmacol. 78(1):65–73. doi: 10.1007/s00228-021-03194-x.
   PubMed Web of Science ®Google Scholar
• Wen HN, He QF, Xiang XQ, Jiao Z, Yu JG. 2022. Predicting drug-drug interactions with physiologically based pharmacokinetic/pharmacodynamic modelling and optimal dosing of apixaban and rivaroxaban with dronedarone co-administration. Thromb Res. 218:24–34. doi: 10.1016/j.thromres.2022.08.007.
   PubMed Web of Science ®Google Scholar
• Wu W, Lin R, Ke M, Ye L, Lin C. 2023. Physiologically based pharmacokinetic modeling characterizes the drug-drug interaction between saxagliptin and rifampicin in patients with renal impairment. J Clin Pharmacol. 63(7):848–858. doi: 10.1002/jcph.2223.
   PubMed Web of Science ®Google Scholar
• Wu D, Sanghavi M, Kollipara S, Ahmed T, Saini AK, Heimbach T. 2023. Physiologically based pharmacokinetics modeling in biopharmaceutics: case studies for establishing the bioequivalence safe space for innovator and generic drugs. Pharm Res. 40(2):337–357. doi: 10.1007/s11095-022-03319-6.
   PubMed Web of Science ®Google Scholar
• Xu R, Tang H, Chen L, Ge W, Yang J. 2021. Developing a physiologically based pharmacokinetic model of apixaban to predict scenarios of drug-drug interactions, renal impairment and paediatric populations. Br J Clin Pharmacol. 87(8):3244–3254. doi: 10.1111/bcp.14743.
   PubMed Web of Science ®Google Scholar
• Yau E, Gertz M, Ogungbenro K, Aarons L, Olivares-Morales A. 2023. A “middle-out approach” for the prediction of human drug disposition from preclinical data using simplified physiologically based pharmacokinetic (PBPK) models. CPT Pharmacometrics Syst Pharmacol. 12(3):346–359. doi: 10.1002/psp4.12915.
   PubMedGoogle Scholar
• Yeo KR, Walsky RL, Jamei M, Rostami-Hodjegan A, Tucker GT. 2011. Prediction of time-dependent CYP3A4 drug-drug interactions by physiologically based pharmacokinetic modelling: impact of inactivation parameters and enzyme turnover. Eur J Pharm Sci. 43(3):160–173. doi: 10.1016/j.ejps.2011.04.008.
   PubMed Web of Science ®Google Scholar
• Zhao P, Lee CA, Kunze KL. 2007. Sequential metabolism is responsible for diltiazem-induced time-dependent loss of CYP3A. Drug Metab Dispos. 35(5):704–712. doi: 10.1124/dmd.106.013847.
   PubMed Web of Science ®Google Scholar
• Zhuang X, Lu C. 2016. PBPK modeling and simulation in drug research and development. Acta Pharm Sin B. 6(5):430–440. doi: 10.1016/j.apsb.2016.04.004.
   PubMed Web of Science ®Google Scholar